42 completed, 6 unknown, 5 terminated, 1 active not recruiting. 56 Phase 1, 8 Phase 2.
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Urodynamics, EG110A, Patient-reported Outcome - Urinary Bladder, Overactive, Spinal Cord Injury | Phase 1 / Phase 2 | Not yet recruiting | Cyllene Therapeutics | 16 | 2026-04-01 | 2025-11-12 |
| Effectiveness of Oral Boldo in Women With Overactive Bladder Oxybutynin Pill, Boldo supplement - Urinary Bladder, Overactive | Phase 1 | Unknown | Universidad de Valparaiso | 10 | 2023-11-01 | 2023-12-08 |
| Reduced-dose Botox for Urgency Incontinence Among Elder Females Botox 50 Unit Injection, Botox 100 Unit Injection - Overactive Bladder, Urinary Incontinence in Old Age | Phase 1 / Phase 2 | Active not recruiting | Dartmouth-Hitchcock Medical Center | 376 | 2023-05-12 | 2026-02-03 |
| Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children Beta3-Agonists, Adrenergic, Anticholinergic drug, Solifenacin - Voiding Disorders, Overactive Bladder | Phase 1 / Phase 2 | Unknown | Mansoura University | 70 | 2022-02-01 | 2022-02-15 |
| Acupuncture Combined With Mirabegron in the Treatment of OAB 50 mg of mirabegron, acupuncture combined with mirabegron. - Overactive Bladder | Phase 1 | Unknown | The Affiliated Ganzhou Hospital of Nanchang University | 75 | 2021-12-01 | 2023-12-26 |
| The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers JLP-2002, Comparator - Overactive Bladder(OAB) | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 42 | 2021-03-13 | 2021-06-14 |
| Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 32 | 2020-08-12 | 2024-03-26 |
| A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B) BAY1817080, [14C]BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 14 | 2020-08-05 | 2023-01-26 |
| Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function BAY1817080, Midazolam - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 37 | 2020-07-23 | 2023-01-20 |
| A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. BR9006-1, BR9006-2 - Benign Prostatic Hyperplasia (BPH), Overactive Bladder | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 36 | 2020-07-20 | 2020-10-28 |
| Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants BAY1817080, Moxifloxacin, Placebo - Cough, Endometriosis | Phase 1 | Completed | Bayer | 42 | 2020-06-18 | 2022-01-24 |
| Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder Botulinum toxin type A injection, Botulinum Toxin Type A Injection [Botox] - Overactive Bladder | Phase 1 | Completed | Hugel | 38 | 2020-05-12 | 2022-04-15 |
| Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants BAY1817080, Matching Placebo - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 36 | 2020-02-15 | 2023-01-26 |
| Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder Meditoxin, Botox - Overactive Bladder | Phase 1 | Completed | Medy-Tox | 30 | 2017-12-13 | 2019-03-27 |
| Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence AHLeveeS System - Overactive Bladder | Phase 1 | Completed | Neuspera Medical, Inc. | 6 | 2017-08-17 | 2018-08-22 |
| Mirabegron For Erectile Dysfunction Mirabegron - Erectile Dysfunction, Overactive Bladder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 20 | 2017-08-01 | 2021-01-05 |
| A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique ultrasound, X-ray - Refractory Overactive Bladder | Phase 1 | Unknown | Beijing Pins Medical Co., Ltd | 30 | 2017-02-01 | 2016-10-27 |
| Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Withdrawn | UroGen Pharma Ltd. | 2016-10-01 | 2017-06-16 | |
| Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects Formulation 1 solabegron, Formulation 2 solabegron - Healthy Subjects, Overactive Bladder | Phase 1 | Completed | Velicept Therapeutics, Inc. | 24 | 2016-10-01 | 2019-04-24 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects DA-8010, Placebo - Overactive Bladder | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 110 | 2016-06-01 | 2016-07-01 |
Showing 20 of 56. Sign in to see all of them.
Prostatic Hyperplasia (6) · Urinary Incontinence (5) · Erectile Dysfunction (2) · Lower Urinary Tract Symptoms (2) · Cough (1) · Endometriosis (1) · Kidney Failure, Chronic (1) · Nocturia (1) · Spinal Cord Injuries (1) · Urinary Bladder Neck Obstruction (1) · Urinary Incontinence, Urge (1)
Female Urogenital Diseases (56) · Female Urogenital Diseases and Pregnancy Complications (56) · Male Urogenital Diseases (56) · Pathological Conditions, Signs and Symptoms (56) · Signs and Symptoms (56) · Urinary Bladder Diseases (56) · Urogenital Diseases (56) · Urologic Diseases (56) · Urological Manifestations (56) · Lower Urinary Tract Symptoms (54) · Genital Diseases (8) · Genital Diseases, Male (7) · Prostatic Diseases (6) · Urination Disorders (6) · Mental Disorders (2)
mirabegron (9) · Solifenacin Succinate (7) · Tolterodine Tartrate (6) · Tamsulosin (4) · fesoterodine (4) · Botulinum Toxins, Type A (3) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (3) · Warfarin (2) · oxybutynin (2) · solabegron (2) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (1) · Adrenergic beta-3 Receptor Agonists (1) · Cephalexin (1) · Chemoprevention (1) · Cholinergic Antagonists (1)
Astellas Pharma Inc (7) · Bayer (5) · Jeil Pharmaceutical Co., Ltd. (4) · Merck Sharp & Dohme LLC (4) · Pfizer (4) · GlaxoSmithKline (3) · Astellas Pharma Europe B.V. (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · UroGen Pharma Ltd. (2) · Urovant Sciences GmbH (2) · Amphora Medical, Inc. (1) · Astellas Pharma Europe Ltd. (1) · Beijing Pins Medical Co., Ltd (1) · Boryung Pharmaceutical Co., Ltd (1) · Cyllene Therapeutics (1)
United States (16) · Netherlands (5) · South Korea (5) · Belgium (4) · Denmark (4) · Poland (3) · Singapore (3) · Canada (2) · Israel (2) · Japan (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Chile (1) · China (1)
Kyung-sang Yu, M.D., Ph.D. (2) · Ami Sidi, Prof MD (1) · An-Hye Kim (1) · Anne C Cooper, MD, MA (1) · Arthur L Burnett, M.D., M.B.A. (1) · Bilal Chughtai, MD (1) · Cornelia Haag-Molkenteller, MD (1) · E A Gormley, MD (1)
PMID 17482910, PMID 19648387, PMID 20189229, PMID 21905086, PMID 37160401, PMID 38044419, PMID 38907175
2009 (1), 2014 (1), 2015 (1)